A month has gone by since the last earnings report for GameStop (GME) . Shares have lost about 18.8% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is GameStop due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, est ...

Core Viewpoint - Kodiak Sciences Inc. has seen a 10.5% increase in share price over the past month, outperforming the S&P 500, but estimates have trended downward, indicating potential challenges ahead [1][2]. Group 1: Earnings and Estimates - The consensus estimate for Kodiak Sciences has shifted downward by 10.35% over the past month [2]. - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4]. Group 2: VGM Scores - Kodiak Sciences has a subpar Growth Score of D and a Momentum Score of F, with an overall aggregate VGM Score of F, placing it in the lowest quintile for investment strategies [3]. Group 3: Industry Performance - Kodiak Sciences is part of the Zacks Medical - Biomedical and Genetics industry, where Apellis Pharmaceuticals has gained 17.7% over the past month [5]. - Apellis Pharmaceuticals reported revenues of $166.8 million, reflecting a year-over-year decline of 3.2%, and is expected to post a loss of $0.44 per share for the current quarter, indicating a 57.1% change from the previous year [6].

Core Viewpoint - Fate Therapeutics has seen a significant increase in share price, gaining approximately 61.5% over the past month, outperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings report [1] Group 1: Earnings and Estimates - The consensus estimate for Fate Therapeutics has shifted upward by 12.68% in the past month, indicating positive revisions [2] - The stock has a Zacks Rank of 2 (Buy), suggesting expectations for above-average returns in the coming months [4] Group 2: VGM Scores - Fate Therapeutics has a subpar Growth Score of D, a Momentum Score of D, and a Value Score of D, placing it in the bottom 40% for investment strategies, resulting in an overall VGM Score of F [3] Group 3: Industry Performance - Fate Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Novavax has reported a revenue of $666.66 million, reflecting a year-over-year increase of 610.3% [5] - Novavax is expected to report a loss of $0.12 per share for the current quarter, with a year-over-year change of -112.1%, and has a Zacks Rank of 3 (Hold) [6]

The J. M. Smucker Company SJM reported mixed fourth-quarter financial results and issued FY26 adjusted EPS guidance below estimates on Tuesday.JM Smucker reported quarterly earnings of $2.31 per share which beat the analyst consensus estimate of $2.24 per share. The company reported quarterly sales of $2.14 billion which missed the analyst consensus estimate of $2.18 billion.“Our fourth quarter and full-year results underscore the demand for our leading brands, the resilience of our business, and our abilit ...

Core Viewpoint - Wall Street analysts have a bearish outlook on UnitedHealth (NYSE: UNH) stock after a significant 23% drop in shares, although there was a slight rebound due to insider buying signaling confidence [1][2] Group 1: Stock Performance and Leadership Changes - Following the resignation of CEO Andrew Witty on May 13, UnitedHealth's stock experienced a sharp decline, which unsettled investors [1][2] - The stock rebounded slightly, rising 4% to $305.25 in pre-market trading after a 6% gain in the previous session [1] Group 2: Financial Outlook and Analyst Revisions - UnitedHealth suspended its 2025 outlook due to rising medical costs in its Medicare Advantage segment and higher-than-expected care activity [2] - Truist Securities analyst David MacDonald reduced the stock price target from $580 to $360, a 37.9% cut, while maintaining a 'Buy' rating [3] - TD Cowen downgraded UnitedHealth shares from Buy to Hold, cutting its price target from $520 to $308, a 40.8% reduction [4] Group 3: Regulatory and Operational Challenges - A Wall Street Journal report indicated that the Department of Justice is investigating UnitedHealth's Medicare Advantage billing practices, which the company denied receiving formal notice about [3] - Analysts noted that UnitedHealth is facing challenges in recapturing target margins in its UnitedHealthcare and Optum Health segments, exacerbated by the DOJ investigation and operational inefficiencies [5][6]

金十数据5月15日讯，华泰证券发表京东物流(02618.HK)报告，基于公司短期资源投入导致成本上升， 下调对公司今年利润率假设，并相应下调对公司今年纯利及非国际财务报告准则盈利预测各3%。对京 东物流目标价由17.8港元下调至16.7港元，目标预测市盈率14.8倍，维持"买入"评级。 华泰证券下调京东物流盈测 料短期成本增长超越收入增长 ...

In its upcoming report, Jack In The Box (JACK) is predicted by Wall Street analysts to post quarterly earnings of $1.13 per share, reflecting a decline of 22.6% compared to the same period last year. Revenues are forecasted to be $341.22 million, representing a year-over-year decrease of 6.6%.The consensus EPS estimate for the quarter has undergone a downward revision of 5.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their i ...

金十数据5月6日讯，瑞银的研究报告指，中国中铁(00390.HK)今年首季的收入及纯利按年跌6%及 23%，整体新合约按年跌10%，主要因为传统板块的增长潜力有限，加上房地产行业仍然触底。同时公 司亦主动转变策略，专注质量多于规模扩张。而海外新合约按年增33%属亮点，受惠于亚洲及非洲楼市 及铁路项目的增长可观。该行指，中国中铁管理层没有更改全年指引(新合约按年增3.1%及收入按年跌 2.4%)，同时管理层认为收入入账及订单在4月加快。该行下调对公司今年至2027年的每股盈利预测12% 至15%，目标价由4.8港元减12%至4.2港元，维持买入评级。 瑞银降中国中铁目标价至4.2港元 公司全年指引不变 ...

The upcoming report from Jones Lang LaSalle (JLL) is expected to reveal quarterly earnings of $2.02 per share, indicating an increase of 13.5% compared to the year-ago period. Analysts forecast revenues of $5.59 billion, representing an increase of 9% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during thi ...

Core Viewpoint - CDW is expected to report quarterly earnings of $1.96 per share, reflecting a 2.1% increase year-over-year, with revenues projected at $4.89 billion, a 0.4% increase compared to the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 2.8%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Public- Government' revenues to be $497.84 million, representing an 8.4% decrease year-over-year [4]. - 'Net sales- Public' are projected at $1.73 billion, indicating a 0.3% increase from the previous year [5]. - 'Public- Healthcare' is expected to reach $630.71 million, reflecting a 7.9% increase year-over-year [5]. - 'Net sales- Small Business' are estimated at $380.47 million, showing a slight decrease of 0.1% from the prior year [5]. - 'Public- Education' is projected at $601.26 million, a 0.8% increase from the previous year [6]. - 'Net sales- Corporate' are expected to be $2.16 billion, indicating a 0.9% increase year-over-year [6]. - 'Net sales- Other' are projected at $637.67 million, reflecting a 1% increase from the prior year [6]. Major Product and Services Estimates - 'Net sales- Major Product and Services- Other' are expected to be $25.82 million, indicating a 2.2% decrease year-over-year [7]. - 'Net sales- Major Product and Services- Hardware- Notebooks/Mobile Devices' are projected at $1.18 billion, reflecting a 3.5% increase [7]. - 'Net sales- Major Product and Services- Hardware- Netcomm Products' are estimated at $587.46 million, indicating a 3.1% increase [8]. - 'Net sales- Major Product and Services- Hardware- Desktops' are expected to reach $260.28 million, reflecting a 0.7% increase [8]. - Overall, 'Net sales- Major Product and Services- Hardware' are projected at $3.54 billion, indicating a slight decrease of 0.1% year-over-year [9]. Stock Performance - CDW shares have increased by 7.2% over the past month, contrasting with a 0.5% decline in the Zacks S&P 500 composite [9].